Is Miralax (polyethylene glycol) polyethylene glycol?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Miralax is Polyethylene Glycol 3350

Yes, Miralax is polyethylene glycol 3350, an osmotic laxative available over the counter for the treatment of constipation. 1

Composition and Mechanism

Polyethylene glycol (PEG) 3350 is the active ingredient in Miralax, with each standard dose containing 17 grams of PEG 3350 1. It works as an osmotic laxative by:

  • Increasing water content in the colon
  • Softening stool
  • Promoting more frequent bowel movements
  • Being poorly absorbed, with minimal systemic effects

Clinical Uses

PEG 3350 (Miralax) is primarily used for:

  1. Treatment of occasional constipation - FDA-approved for short-term use 1
  2. Management of chronic constipation - Supported by clinical evidence for longer-term use 2, 3
  3. Bowel preparation for colonoscopy - Although not FDA-approved for this purpose, it is widely used in "split-dose" regimens 4
  4. Treatment of constipation in irritable bowel syndrome with constipation (IBS-C) - Recommended by guidelines 4

Efficacy and Safety

PEG 3350 has demonstrated strong efficacy and safety profiles:

  • Efficacy: Clinical trials show successful treatment in 52-61% of patients with chronic constipation versus 11-22% with placebo 3
  • Long-term safety: Studies demonstrate safety for up to 12 months of continuous use with no evidence of tachyphylaxis (decreased response over time) 2
  • Elderly patients: Similar efficacy and safety profiles in elderly populations 2, 3
  • Rapid onset: Higher doses (68g) can provide relief within 24 hours for acute constipation 5

Important Clinical Considerations

Advantages of PEG 3350:

  • Minimal systemic absorption
  • No clinically significant changes in electrolytes with long-term use 2
  • Better tolerability compared to other laxatives 6
  • Can be used in patients with renal insufficiency, congestive heart failure, and advanced liver disease due to its iso-osmotic properties 4

Side Effects:

  • Most common: diarrhea, loose stools, flatulence, and nausea 2, 3
  • Generally mild to moderate in severity
  • No significant changes in hematology or blood chemistry, including electrolytes 2

Contraindications:

  • Allergy to polyethylene glycol 1
  • Bowel obstruction, ileus 4

Special Populations

Children:

  • Polyethylene glycol is recommended as a first-line treatment for constipation in children 7
  • Standard dose is 17g daily mixed in 4-8 ounces of liquid 7

Elderly:

  • Safe and effective in elderly patients with similar efficacy to younger adults 2, 3
  • No dose adjustment required based on age

Formulations and Dosing

  • Standard dose: 17g once daily mixed in 4-8 ounces of liquid 1, 8
  • Duration: FDA-approved for short-term use, but clinical evidence supports safety for up to 12 months 2
  • Bowel preparation: When used for colonoscopy preparation, typically administered in split-dose regimens, though this is not an FDA-approved indication 4

Important Note on Off-Label Use

The US Multi-Society Task Force on Colorectal Cancer notes that using over-the-counter PEG-3350 (Miralax) mixed with sports drinks for bowel preparation before colonoscopy, while widely practiced, is not FDA-approved for this purpose 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Overnight efficacy of polyethylene glycol laxative.

The American journal of gastroenterology, 2002

Guideline

Gastrointestinal Health in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

OTC polyethylene glycol 3350 and pharmacists' role in managing constipation.

Journal of the American Pharmacists Association : JAPhA, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.